GASTROPROTECTIVE NSAIDs

Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice?

BACKGROUND Two strategies for prevention of upper gastrointestinal (UGI) events for nonselective nonsteroidal anti-inflammatory drug (nsNSAID) users are replacement of the nsNSAID by a cyclo-oxygenase-2-selective inhibitor (coxib) or co-prescription of a gastroprotective agent (GPA). AIM To identify whether and in whom either of these strategies should be preferred in daily practice. METHOD...

Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in

27 Urinary bladder cancer prevention studies were performed with the nonsteroidal anti28 inflammatory drugs (NSAIDs) naproxen (a standard NSAID with a good cardiovascular profile), 29 sulindac, and their nitric oxide (NO) derivatives. Additionally, the effects of the ornithine 30 decarboxylase inhibitor, difluoromethylornithine (DFMO), alone or combined with a suboptimal 31 dose of naproxen or ...

Flavonoids with gastroprotective activity.

Peptic ulcers are a common disorder of the entire gastrointestinal tract that occurs mainly in the stomach and the proximal duodenum. This disease is multifactorial and its treatment faces great difficulties due to the limited effectiveness and severe side effects of the currently available drugs. The use of natural products for the prevention and treatment of different pathologies is continuou...

NSAIDs as Cancer Preventive Agents NSAIDs as Cancer Preventive Agents

Introduction: Targeting of inflammatory states with non-steroidal anti-inflammatory drugs (NSAID’S) is an attractive proposition for cancer prevention. There is abundant epidemiological and experimental evidence that NSAID’S can inhibit tumour development in a number of organs and such drugs have given positive results in human intervention studies. It is hoped that problems with side effects c...

Gastroprotective strategy in aspirin users.